Q2 2024 · 13F-HR
Kynam Capital Management, LPholdings as filed
Filed 2024-08-14 · accession 0001085146-24-003915
$1.30B
Reported value
26
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 632307104 | NTRA | NATERA INC | $218.1M | 16.8% | 2,014,408 | Common | SOLE |
| 92532F100 | VRTX | VERTEX PHARMACEUTICALS INC | $154.7M | 11.9% | 330,000 | PUT | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $125.4M | 9.67% | 3,388,967 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $117.5M | 9.06% | 5,722,057 | Common | SOLE |
| 78462F103 | SPY | SPDR S&P 500 ETF TR | $109.1M | 8.42% | 200,000 | PUT | SOLE |
| 268158201 | DVAX | DYNAVAX TECHNOLOGIES CORP | $79.5M | 6.14% | 7,082,562 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $78.1M | 6.02% | 9,260,385 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $67.0M | 5.17% | 1,000,000 | CALL | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $56.9M | 4.39% | 753,240 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $55.8M | 4.31% | 1,543,669 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $54.5M | 4.21% | 8,826,710 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $27.7M | 2.14% | 800,000 | Common | SOLE |
| 901384107 | TSVT* | 2SEVENTY BIO INC | $22.9M | 1.77% | 5,953,825 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $22.8M | 1.76% | 1,750,000 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $19.8M | 1.53% | 3,975,521 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $16.6M | 1.28% | 2,021,659 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $11.0M | 0.85% | 916,574 | Common | SOLE |
| 46333X108 | IRWD | IRONWOOD PHARMACEUTICALS INC | $10.7M | 0.83% | 1,641,891 | Common | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $10.4M | 0.81% | 43,000 | PUT | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $9.1M | 0.70% | 566,715 | Common | SOLE |
| 023111206 | — | AMARIN CORP PLC | $8.4M | 0.65% | 12,155,830 | Common | SOLE |
| 12233L206 | BNR | BURNING ROCK BIOTECH LTD | $6.3M | 0.48% | 974,668 | Common | SOLE |
| 869367102 | — | SUTRO BIOPHARMA INC | $5.9M | 0.46% | 2,023,683 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $3.7M | 0.28% | 831,310 | Common | SOLE |
| 142038108 | CRBU | CARIBOU BIOSCIENCES INC | $2.7M | 0.21% | 1,646,702 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $1.7M | 0.13% | 53,911 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.